VB15010 / Shenzhen Yangli Pharma - LARVOL DELTA

Preliminary safety, PK and efficacy of a PARP1 selective inhibitor VB15010 in patients with advanced solid tumors in phase 1/2 study (AACR-NCI-EORTC 2025) - P1/2 | "Unlike first-generation PARP inhibitors (e.g., olaparib, niraparib), which inhibit both PARP1 and PARP2, VB15010 minimizes PARP2 inhibition, which is implicated in hematologic toxicities such as anemia, neutropenia, and thrombocytopenia. ConclusionsVB15010 demonstrated favorable tolerability, promising PK/PD properties, and preliminary antitumor activity in advanced solid tumors with HRR gene mutations. These results support further clinical development in this patient population."

Clinical • Metastases • P1/2 data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • HRD • PARP2

Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients with Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=188 | Recruiting | Sponsor: Shenzhen Yangli Pharmaceutical Technology Co., Ltd

New P1/2 trial • Biliary Cancer • Breast Cancer • Colorectal Cancer • Hepatology • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Solid Tumor

Simcere Pharmaceuticals' Phase III study of innovative anti-influenza drug was successful; Junshi Biologics' first-quarter revenue was 380 million yuan [Google translation] (163.com) - "On April 29, according to the CDE official website, Hengrui Medicine’s injection SHR-9839 was approved for clinical use and is planned to be combined with SHR-A2009, or SHR-A1921, or ametinib, or combined with chemotherapy to treat advanced solid tumors...according to the CDE official website, Yangli Pharmaceutical VB15010 tablets were approved for clinical use and plans to conduct research on the treatment of advanced solid tumors....according to the CDE official website, BeiGene’s BGB-A3055 for injection was approved for clinical use and plans to conduct research on the treatment of advanced or metastatic solid tumors."

New trial • Oncology • Solid Tumor

VB15010 is a potent PARP1 selective inhibitor and durable trapper with improved pharmacological activities (AACR 2024) - "Currently approved PARP inhibitors, such as olaparib, are pan-PARP inhibitors targeting PARP1, PARP2, and other PARP family members. Collectively, with improved PK-PD properties, including durable DNA trapping capability, higher apoptosis-inducing potency, and favorable tumor-to-plasma distribution ratio, as well as potent antitumor activity, VB15010 may achieve enhanced clinical efficacy and reduced hematological toxicity with a higher therapeutic index in patients. Its IND filing is expected in the first quarter of 2024."

Oncology • BRCA2 • HRD • PARP2